If Nektar Therapeutics wins FDA approval this summer for an opioid painkiller it designed to be less addictive than other opioids, another company will usher the new product onto the market.
San Francisco-based Nektar (NASDAQ: NKTR) announced Thursday that it formed Inheris Biopharma to take the reins on pain drug NKTR-181, as well as several preclinical compounds for central nervous system disorders. The new company, a wholly owned subsidiary of Nektar, will be headquartered in northern New Jersey. No financing details were disclosed. Nektar’s remaining drug pipeline includes experimental treatments for cancer and autoimmune diseases.
UNDERWRITERS AND PARTNERS